The TOR/mTOR Pathway and Ageing

What It Is

The mechanistic target of rapamycin (mTOR) is a conserved protein kinase that integrates nutrient availability, growth factors, and cellular energy status to regulate cell growth and metabolism. It operates in two multi-protein complexes, mTORC1 and mTORC2, which have distinct upstream inputs and downstream effects. [1] [2] [3]

Role in Ageing

In the hallmarks framework, deregulated nutrient sensing is a core feature of ageing, and mTOR sits at the center of that control. Elevated mTORC1 activity can shift cells toward growth and biosynthesis while suppressing cellular maintenance programs such as autophagy, a trade-off that is often discussed in aging biology. [4] [2] [8]

Evidence from Research

Across model organisms, reduced TOR/mTOR signaling is associated with extended lifespan. In mice, dietary rapamycin has extended lifespan in genetically heterogeneous cohorts and in inbred strains, supporting a conserved role for mTOR in mammalian ageing. [5] [6]

Human evidence is more limited but includes clinical studies showing that low-dose mTOR pathway inhibition can enhance vaccine responses and reduce infection rates in older adults. These trials demonstrate physiological effects but do not establish effects on human lifespan. [7] [9]

Connections to Other Processes

mTOR connects nutrient sensing to multiple hallmarks of ageing, including loss of proteostasis, mitochondrial dysfunction, and altered intercellular communication. Because mTOR regulates autophagy and protein synthesis, it intersects with pathways that influence cellular damage accumulation and stress responses. These links are often discussed alongside the hallmarks of ageing and related glossary concepts such as cellular senescence and mitochondrial dysfunction. [4] [2] [8]

Current Understanding and Limitations

mTOR is a central coordinator of growth and immune function, so altering its activity can produce trade-offs. The same pathway that influences ageing biology also supports wound healing, metabolism, and immune responses, which complicates translation. Human trials to date focus on immune outcomes and are short-term, leaving open questions about long-term safety, dosing, and population differences. [7] [9]

Summary

The TOR/mTOR pathway is a fundamental nutrient-sensing system that links growth to cellular maintenance. Research across species supports its relevance to ageing, but human evidence remains early and mostly indirect. Current understanding emphasizes complex trade-offs rather than a single, simple intervention pathway. [4] [5] [7]

References

1. Schmelzle, T., & Hall, M. N. "TOR, a central controller of cell growth." Cell (2000). https://pubmed.ncbi.nlm.nih.gov/11057898/
2. Laplante, M., & Sabatini, D. M. "mTOR signaling in growth control and disease." Cell (2012). https://pmc.ncbi.nlm.nih.gov/articles/PMC3331679/
3. Saxton, R. A., & Sabatini, D. M. "mTOR signaling in growth, metabolism, and disease." Cell (2017). https://pmc.ncbi.nlm.nih.gov/articles/PMC5394987/
4. López-Otín, C. et al. "Hallmarks of aging: An expanding universe." Cell (2023). https://doi.org/10.1016/j.cell.2022.11.001
5. Harrison, D. E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature (2009). https://www.nature.com/articles/nature08221
6. Wilkinson, J. E. et al. "Rapamycin extends life and health in C57BL/6 mice." Journals of Gerontology: Series A (2014). https://pubmed.ncbi.nlm.nih.gov/23682161/
7. Mannick, J. B. et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine (2014). https://pubmed.ncbi.nlm.nih.gov/25540326/
8. Al-Bari, M. A. A. "mTORC1 as the main gateway to autophagy." Vitamins and Hormones (2018). https://pmc.ncbi.nlm.nih.gov/articles/PMC5869864/
9. Mannick, J. B. et al. "TORC1 inhibition enhances immune function and reduces infections in the elderly." Science Translational Medicine (2018). https://pubmed.ncbi.nlm.nih.gov/29997249/